A Phase 1 Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Patients (pts) with Certain Relapsed or Refractory (R/R) Hematologic Malignancies (HMs)

被引：2

作者：

Sun, Mingyuan ^{[1
]}

Qi, Junyuan ^{[1
]}

Chen, Zi ^{[2
]}

Zhang, Hongli ^{[2
]}

Song, Yongping ^{[3
]}

Shen, Aizong ^{[4
]}

Liu, Huilan ^{[4
]}

Huang, Jianying ^{[5
]}

Zhou, Fuling ^{[5
]}

Jin, Jie ^{[6
]}

Lu, Ming ^{[7
]}

Ahmad, Mohammad ^{[7
]}

Men, Lichuang ^{[2
]}

Cen, Wan ^{[2
]}

Yang, Dajun ^{[2
,8
]}

Wang, Jianxiang ^{[1
]}

Zhai, Yifan ^{[2
,7
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, State Key Lab Expt Hematol, Tianjin, Peoples R China

[2] Ascentage Pharma Suzhou Co Ltd, Suzhou, Peoples R China

[3] Zhengzhou Univ, Dept Hematol, Affiliated Canc Hosp, Zhengzhou, Peoples R China

[4] USTC Anhui Prov Hosp, Affiliated Hosp 1, Hefei, Peoples R China

[5] Wuhan Univ, Zhongnan Hosp, Wuhan, Peoples R China

[6] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China

[7] Ascentage Pharma Grp Inc, Rockville, MD USA

[8] Sun Yat Sen Univ, State Key Lab Oncol South China Collaborat Innova, Canc Ctr, Guangzhou, Peoples R China

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-152235

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3730

引用

页码：3730 / +

页数：4

共 50 条

[1] First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).
Ailawadhi, Sikander
Chanan-Khan, Asher Alban Akmal
Chen, Zi
Huang, Bo
Konopleva, Marina
Brander, Danielle M.
Rizzieri, David
Lasica, Masa
Tam, Constantine Si Lun
Yannakou, Costas K.
Prince, H. Miles
Davids, Matthew Steven
He, Zhicong
Lu, Ming
Ahmad, Mohammad
Li, Mingyu
Liang, Zhiyan
Mudenda, Boyd
Yang, Dajun
Zhai, Yifan
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[2] A phase Ib/II study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL).
Li, Jianyong
Zhou, Keshu
Nian, Weiqi
Cui, Guohui
Wang, Jishi
Zhang, Xiaoping
Cen, Hong
Li, Fei
Yi, Shuhua
Feng, Ru
Xu, Chongyuan
Qian, Wenbin
Liu, Lihong
Li, Caixia
Zhao, Xielan
Chen, Zi
Qiao, Junxiao
Zhang, Hongli
Ahmad, Mohammad
Zhai, Yifan
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[3] First-in-Human Study of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Patients With Relapsed/Refractory CLL and Other Hematologic Malignancies
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (07) : 10 - 11
[4] Safety and Efficacy of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Relapsed or Refractory (R/R) or Treatment-Naive (TN) Patients (Pts) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Other Myeloid Neoplasms
Wang, Huafeng
Wei, Xudong
Jiang, Qian
He, Wenjun
Li, Qiubai
Liang, Yang
Weng, Jianyu
Chen, Suning
Ma, Hongbing
Chang, Chukang
Xu, Yajing
He, Qun
Chen, Zi
Liu, Lihui
Men, Lichuang
Cong, Danhua
Zhang, Zhang
Yang, Dajun
Zhai, Yifan
Jie, Jin
BLOOD, 2023, 142
[5] First-in-human open-label study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and other hematologic malignancies
Ailawadhi, Sikander
Chen, Zi
Huang, Bo
Paulus, Aneel
Collins, Mary
Fu, Lei
Li, Mingyu
Ahmad, Mohammad
Men, Lichuang
Wang, Hengbang
Davids, Matthew
Liang, Eric
Mekala, Divya
He, Zhicong
Lasica, Masa
Yannakou, Costas
Parrondo, Ricardo
Glass, Laura
Yang, Dajun
Chanan-Khan, Asher
Zhai, Yifan
LEUKEMIA & LYMPHOMA, 2023, 64 : S76 - S77
[6] Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy
Paulus, Aneel
Manna, Alak
Wang, Hengbang
Chen, Jianyong
Min, Ping
Yin, Yan
Dutta, Navnita
Halder, Nabanita
Ciccio, Gina
Copland, John
Han, Bing
Bai, Longchuan
Liu, Liu
Wang, Mi
McEachern, Donna
Przybranowski, Sally
Yang, Chao-Yie
Stuckey, Jeanne
Wu, Depei
Li, Caixia
Ryan, Jeremy
Letai, Anthony
Ailawadhi, Sikander
Yang, Dajun
Wang, Shaomeng
Chanan-Khan, Asher
Zhai, Yifan
LEUKEMIA & LYMPHOMA, 2023, 64 : S79 - S79
[7] Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
Deng, Jing
Paulus, Aneel
Fang, Douglas D.
Manna, Alak
Wang, Guangfeng
Wang, Hengbang
Zhu, Saijie
Chen, Jianyong
Min, Ping
Yin, Yan
Dutta, Navnita
Halder, Nabanita
Ciccio, Gina
Copland III, John A.
Miller, James
Han, Bing
Bai, Longchuan
Liu, Liu
Wang, Mi
McEachern, Donna
Przybranowski, Sally
Yang, Chao-Yie
Stuckey, Jeanne A.
Wu, Depei
Li, Caixia
Ryan, Jeremy
Letai, Anthony
Ailawadhi, Sikander
Yang, Dajun
Wang, Shaomeng
Chanan-Khan, Asher
Zhai, Yifan
CLINICAL CANCER RESEARCH, 2022, 28 (24) : 5455 - 5468
[8] Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Combination with Azacitidine in Treatment of Patients with Myelodysplastic Syndrome (MDS)
Wang, Huafeng
Wei, Xudong
Liang, Yang
Weng, Jianyu
He, Wenjuan
Chang, Chunkang
Chen, Suning
Ma, Hongbing
Chen, Zi
Men, Lichuang
Liu, Lihui
Tian, Xiaohong
Zhang, Zhang
Cong, Danhua
Yang, Dajun
Zhai, Yifan
Jin, Jie
BLOOD, 2024, 144 : 3202 - 3203
[9] Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenstrom macroglobulinemia (WM).
Lasica, Masa
Ailawadhi, Sikander
Fu, Chengcheng
Thomas, Sheeba K.
Wu, Depei
Yi, Shuhua
Siddiqi, Tanya
Yin, Qingsong
Allan, John N.
Chen, Wenming
Matous, Jeffrey V.
Feng, Ru
Chen, Zi
Yu, Min
Li, Mingyu
He, Zicong
Ahmad, Mohammad
Wang, Hengbang
Chanan-Khan, Asher Alban Akmal
Zhai, Yifan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[10] Preliminary data of a phase 1b/2 study of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenstrom macroglobulinemia (WM)
Ailawadhi, Sikander
Lasica, Masa
Fu, Chengcheng
Thomas, Sheeba K.
Wu, Depei
Yi, Shuhua
Siddiqi, Tanya
Yin, Qingsong
Allan, John N.
Chen, Wenming
Matous, Jeffrey V.
Feng, Ru
Chen, Zi
Yu, Min
Li, Mingyu
He, Zicong
Ahmad, Mohammad
Wang, Hengbang
Chanan-Khan, Asher Alban Akmal
Zhai, Yifan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →